Keywords: mylan, sees, sales, drop, 2nd, qtr, usa-based
Mylan sees sales drop 15% for 2nd qtr
Article | 08 November 2004
USA-based generic drugmaker Mylan Laboratories saw its profit slashed nearly in half for its fiscal second quarter, ended September 30, 2004. The ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
